Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

1 profitable stock with solid fundamentals and 2 facing headwinds

November 05, 2026

Collegium Pharmaceutical (NASDAQ:COLL) Posts Mixed Q3 as EPS Beats, Revenue Misses, and Guidance Holds ↗

Performance

52-Week Range 50.1% below 52-week high

25.32

21.4352W Low 50.7952W High

1 Week

23.711W Low 25.131W High

Collegium Pharmaceutical, Inc. - Common Stock (COLL) traded between $21.43 and $50.79 over the past 52 weeks and last traded at $25.32, 50.1% below its 52-week high. Over the past week it ranged between $23.71 and $25.13.

Past 12 Months

+4.6%

+17.6%

-10.1%

-27.3%

-44.4%

-46.5%

1W +$1.11

1M +$3.79

3M -$2.83

6M -$9.51

YTD -$20.21

1Y -$22.03

COLL was -46.5% over the past year, -27.3% over six months, -44.4% year to date, +4.6% in the last week.

12 Months vs Market

COLL

-46.5%

DIA

+8.2%

SPY

+10.1%

QQQ

+9.3%

IWM

+13.7%

Over the past 12 months COLL returned -46.5% versus DIA (Dow) +8.2%, SPY (S&P 500) +10.1%, QQQ (Nasdaq 100) +9.3% and IWM (Russell 2000) +13.7%.

Volume & Liquidity 0.24× 3-mo avg

Today 191,241 3-mo avg 793.4K

647.3K

681.2K

793.4K

635.4K

YTD

585.3K

578.1K

COLL most recently traded 191,241 shares against a 3-month average daily volume of 793.4K.

More News

Collegium (COLL) Q3 2026 Earnings Call Transcript ↗

November 05, 2026

Via The Motley Fool

Collegium Pharmaceutical Q3 Earnings Call Highlights ↗

November 05, 2026

Via MarketBeat

November 05, 2026

Via Chartmill

Collegium Pharmaceutical (NASDAQ:COLL) Tumbles on Revenue Miss and Lowered Guidance ↗

August 06, 2026

Via Chartmill

Collegium Pharmaceutical (NASDAQ:COLL) posts in line Q3 2026 sales and full year revenue guidance above estimates, stock soars

November 05, 2026

Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance

November 05, 2026

Collegium Pharmaceutical (COLL) Q3 earnings: what to expect

November 03, 2026

1 of Wall Street’s favorite stocks with promising prospects and 2 we turn down

October 30, 2026

Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts

October 29, 2026

Q2 earnings highs and lows: Collegium Pharmaceutical (NASDAQ:COLL) vs the rest of the branded pharmaceuticals stocks

October 25, 2026

Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026

October 22, 2026

Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses

October 21, 2026

Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life

October 06, 2026

3 Healthcare Stocks That Concern Us

September 30, 2026

3 Value Stocks That Fall Short

September 28, 2026

1 Oversold Stock Ready to Bounce Back and 2 We Find Risky

September 22, 2026

1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm

September 21, 2026

Collegium to Participate in Upcoming Investor Conferences

September 08, 2026

Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Via The Motley Fool

Collegium Announces $50 Million Accelerated Share Repurchase Program

August 13, 2026

5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call

August 13, 2026

COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance

August 07, 2026